Abstract
Ribavirin use and higher ribavirin doses are associated with accelerated viral decay during the very early phase of ant-HCV therapy. An interference of abacavir with ribavirin intracellular phosphorilation has been hypothesized. Thus, concurrent abacavir use should impair the early phases of viral decay during anti HCV treatment. A negative interaction seem to be confirmed by preliminary data from retrospective studies showing a negative impact of abacavir use on the sustained response to pegylated interferon and ribavirin combination treatment in HIV infected patients with chronic hepatitis C. However this association could be biased by confounders and not due to a reduced potency of anti HCV treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
